GLP-1 obesity drug sales value jumped 72% in September 2026 as units fell 10%
The market report credits the rise in sales value to new generics and steady prices, with Eli Lilly's tirzepatide named among the drivers.
Recap by typeshit. Post by Facebook on Facebook.